Samsung Bioepis

Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Fierce Pharma
Merck
Samsung Bioepis
Lantus
insulin
diabetes
biosimilars
Mylan Labs
Biocon
Flag link:
Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis
Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis
Endpoints
Biogen
Samsung Bioepis
biosimilars
M&A
Flag link:
Biogen to increase stake in biosimilar developer Samsung Bioepis
Biogen to increase stake in biosimilar developer Samsung Bioepis
Biopharma Dive
Biogen
biosimilars
Samsung Bioepis
Flag link:
Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
Yahoo/Reuters
Janssen
Samsung Bioepis
Remicade
biosimilars
rheumatoid arthritis
Flag link:
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
BioPharma Dive
Samsung Bioepis
EMA
Europe
biosimilars
Herceptin
Roche
breast cancer
Flag link:
Biogen, Samsung Humira copy wins EU approval
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Biogen
Samsung Bioepis
Europe
Humira
AbbVie
Imraldi
biosimilars
Flag link:
Samsung Bioepis switches gears, moves from knockoffs to new drugs with fast-changing Takeda
Samsung Bioepis switches gears, moves from knockoffs to new drugs with fast-changing Takeda
Endpoints
Samsung Bioepis
Takeda
drug development
TAK-671
pancreatitis
Flag link:
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Endpoints
Samsung Bioepis
Remicade
FDA
biosimilars
JNJ
GSK
Benlysta
lupus
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
J&J fires off legal salvo to block Samsung's Remicade biosim launch
J&J fires off legal salvo to block Samsung's Remicade biosim launch
Fierce Pharma
JNJ
Samsung Bioepis
Remicade
biosimilar
Flag link:
Second biosimilar of Remicade approved in the US, but J&J not rattled
Second biosimilar of Remicade approved in the US, but J&J not rattled
BioPharma Dive
Remicade
JNJ
biosimilars
Renflexis
Merck
Samsung Bioepis
Flag link:
Hunting growth, Samsung races to get up to speed on biosimilar drugs
Hunting growth, Samsung races to get up to speed on biosimilar drugs
Yahoo/Reuters
Samsung Bioepis
biosimilars
Flag link:
Samsung Bioepis notches European Commission nod for Remicade biosim
Samsung Bioepis notches European Commission nod for Remicade biosim
Fierce Pharma
Samsung Bioepis
Europe
Flixabi
Remicade
biosimilars
JNJ
Flag link:
Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S.
Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S.
Yahoo/Reuters
Samsung Bioepis
Remicade
biosimilars
FDA
rheumatoid arthritis
JNJ
Flag link:
Samsung brings in the lawyers for biosimilars push
Samsung brings in the lawyers for biosimilars push
Yahoo/Reuters
Samsung Bioepis
AbbVie
biosimilars
Humira
Flag link:
Biogen Inc. Takes Aim at Johnson & Johnson
Biogen Inc. Takes Aim at Johnson & Johnson
Motley Fool
Biogen
JNJ
Samsung Bioepis
Remicade
Flag link:
Amgen Loses Enbrel to Biogen in Europe; Can It Cope?
Amgen Loses Enbrel to Biogen in Europe; Can It Cope?
Bidness, ETC
Amgen
Biogen
Europe
Enbrel
Samsung Bioepis
biosimilars
Flag link:
Merck and Samsung notch their first biosimilar victory with Enbrel knockoff
Merck and Samsung notch their first biosimilar victory with Enbrel knockoff
Fierce Biotech
Merck
Samsung Bioepis
Enbrel
biosimilars
Amgen
rheumatoid arthritis
Flag link:
Merck and Samsung's Humira biosimilar comes through in Phase III
Merck and Samsung's Humira biosimilar comes through in Phase III
Fierce Biotech
Merck
Humira
biosimilars
SB5
Samsung Bioepis
AbbVie
rheumatoid arthritis
Flag link:
Samsung and Biogen plot an IPO for their biosimilars JV
Samsung and Biogen plot an IPO for their biosimilars JV
Fierce Biotech
Samsung
Biogen
IPOs
biosimilars
Samsung Bioepis
Flag link:

Pages